Core Insights - The article reports that Innovent Biologics (01801.HK) has entered into a global strategic collaboration with Takeda Pharmaceutical to accelerate the development of its next-generation immuno-oncology (IO) and antibody-drug conjugate (ADC) therapies, aiming to expand its global market value [1] Financial Details - The total amount of the collaboration can reach up to $11.4 billion, which includes an upfront payment of $1.2 billion and potential milestone payments of $10.2 billion [1] - This collaboration sets a new record for business development (BD) transactions in China's innovative drug industry [1] Market Reaction - On October 22, Innovent Biologics opened 9.9% higher in the secondary market but experienced fluctuations, closing at HKD 85.2 per share, down 1.96%, with a total market capitalization of HKD 146 billion [1]
信达生物与武田制药达成全球战略合作，交易额最高114亿美元